ProvingImpact
By John Buschiazzo
Life sciences organizations are operating under sustained pressure. Margins are scrutinized. Product launches must land flawlessly. Compliance standards continue to evolve. Artificial intelligence (AI) is reshaping commercial and corporate workflows.
In this environment, learning and development (L&D) functions are not judged by activity. They are judged by contribution. Yet too often, L&D still measures what validates the profession rather than what advances the enterprise.
A chief learning officer once built a sophisticated return-on-investment (ROI) model to prove her team’s value. The methodology was rigorous. The data was clean. The layoffs came anyway.
The executive team was not asking for ROI. They were asking:
Are we increasing revenue per representative?
Are we reducing time-to-proficiency for new hires?
Are we accelerating adoption of AI-enabled selling tools?
Are we minimizing compliance risk during launch?
No one had asked what success meant to them. That is the gap.
ROI has its place. But in isolation, it rarely drives enterprise decisions.
In regulated, performance-driven environments, leaders allocate resources based on business indicators:
Field force productivity.
Launch readiness.
Audit findings.
Retention of high-value talent.
Speed of execution.
If your measurement framework does not connect directly to those indicators, it will not influence budget conversations.
Instead of building measurement models independently, partner with finance, compliance and commercial operations. Define success together. Align metrics to the same dashboards executives review each quarter.
When learning metrics appear alongside business metrics, credibility accelerates.
Consider a national sales meeting introducing an AI-enabled customer relationship management solution. The traditional L&D approach might measure:
Attendance.
Satisfaction.
Knowledge retention.
A business-aligned approach would also track:
Utilization rates post-meeting.
Reduction in administrative time per rep.
Increase in customer-facing time.
Early indicators of lift in call quality or sales velocity.
If AI adoption lags, that is not just a training issue. It is a revenue issue. Measurement must make that connection explicit.
Attendance and reaction data are often criticized as insufficient. In reality, they are early signals.
In a hybrid, overscheduled workforce, voluntary participation reflects perceived value. Completion rates matter. Repeat engagement matters.
Reaction data also matters when framed properly. Ask:
Was this relevant to current market conditions?
Can this be applied in the next 30 days?
Did this increase confidence in using new systems or AI tools?
When relevance and confidence increase, adoption often follows. The issue is not which level of measurement you use. The issue is whether each metric ladders to enterprise impact.
Most life sciences companies already invest heavily in engagement analytics. Research from Gallup continues to show strong correlations between engagement, productivity, profitability and retention.
When launching major initiatives, compare engagement scores of participants versus nonparticipants. Monitor retention in critical roles. Examine internal mobility patterns.
You do not need new systems. You need stronger linkage between development activity and outcomes leaders already track.
AI is embedded in commercial operations, medical affairs and corporate functions. The capability gap is real.
Your measurement strategy must answer:
Did time-to-proficiency decrease?
Did managers increase effectiveness in leading hybrid, AI-enabled teams?
Did we reduce compliance exposure through better decision-making?
Did productivity improve in measurable ways?
If L&D cannot demonstrate impact in these areas, it risks being perceived as supportive rather than strategic during transformation.
Create a cross-functional advisory group representing commercial, medical, compliance and corporate stakeholders.
Ask them:
What outcomes justify continued investment?
What indicators influence resource allocation?
Where does capability development accelerate execution?
When business leaders help define success metrics, they defend the function that delivers them.
Alignment becomes shared ownership.
In life sciences, performance, compliance and speed are non-negotiable.
L&D initiatives must serve a defined business purpose and drive measurable outcomes tied directly to enterprise priorities. Not activity. Not elegance. Not theoretical ROI.
Ask your executive team three questions:
What outcomes matter most this year?
Which indicators determine funding decisions?
Where can capability materially accelerate those results?
Then build your measurement strategy backward from those answers. Because in today’s environment, learning is not competing for approval. It is competing for relevance.
If your metrics do not move the numbers leaders are held accountable for, your programs are invisible to the only audience that ultimately matters.
And in a margin-driven, AI-accelerated industry, invisible functions are not restructured. They are removed.
John Buschiazzo is relationship manager for Training Pros. Email John at john.buschiazzo@trainingpros.com or connect through linkedin.com/in/johnbuschiazzo.
